by Maria Zannes | Mar 14, 2025 | Articles, News
As published by 360Dx, March 14, 2025 By Greg Cima NEW YORK – BioAffinity Technologies said that it is cutting costs in its pathology lab and preparing to start a clinical trial for its sputum-based lung cancer test in a bid to expand into a national player in cancer...
by Maria Zannes | Mar 7, 2025 | Articles, News
As published in the San Antonio Business Journal, March 7, 2025 By W. Scott Bailey – Senior Reporter BioAffinity Technologies Inc., one of San Antonio’s more promising early-stage biotech companies, is making tactical changes to improve its financial performance and...
by Maria Zannes | Nov 8, 2024 | Articles, News
The Alamo City biotech has secured a key win in Japan that could make it a key player in a nearly billion-dollar industry. As published in the San Antonio Business Journal By W. Scott Bailey – Senior Reporter, San Antonio Business Journal BioAffinity Technologies Inc....
by Maria Zannes | Oct 16, 2024 | Articles, News
As published in Mergermarket By Deborah Balshem and Jeff Sheban Summary • Medicare reimbursement providing tailwinds • Expansion into government market imminent • Analyst sees labs chains among potential buyers bioAffinity Technologies [NASDAQ:BIAF], a healthcare...
by Maria Zannes | Oct 13, 2024 | Articles, News
With a San Antonio biotech firm’s test, your phlegm could help save you from cancer. As published by the San Antonio Express-News By Brandon Lingle, Staff Writer The screening method developed by bio Affinity Technologies Inc. uses Al-aided computer analysis...
by Maria Zannes | Oct 11, 2024 | Articles, News
The Alamo City company has gained new commercial access that could greatly expand its reach and its revenue. As published in the San Antonio Business Journal By W. Scott Bailey – Senior Reporter, San Antonio Business Journal BioAffinity Technologies Inc. has reached a...
